This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Tricida.

Información clave

57.3%

Tasa de crecimiento de los beneficios

58.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	29 Mar 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Dec 14

Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%

Dec 09

Tricida's Veverimer CRL And Regulatory Updates: An Analysis

Nov 17

Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

Oct 29

Previsiones de crecimiento de beneficios e ingresos

OTCPK:TCDA.Q - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	N/A	-58	-29	-29	1
12/31/2022	N/A	-109	-89	-89	1
9/30/2022	N/A	-134	-109	-109	N/A
6/30/2022	N/A	-148	-119	-119	N/A
3/31/2022	N/A	-153	-136	-135	N/A
12/31/2021	N/A	-177	-140	-140	N/A
9/30/2021	N/A	-181	-145	-144	N/A
6/30/2021	N/A	-219	-177	-176	N/A
3/31/2021	N/A	-244	-212	-211	N/A
12/31/2020	N/A	-265	-233	-231	N/A
9/30/2020	N/A	-268	-220	-219	N/A
6/30/2020	N/A	-235	-202	-201	N/A
3/31/2020	N/A	-213	-158	-157	N/A
12/31/2019	N/A	-177	-131	-130	N/A
9/30/2019	N/A	-146	-134	-133	N/A
6/30/2019	N/A	-131	-119	-118	N/A
3/31/2019	N/A	-120	-104	-104	N/A
12/31/2018	N/A	-103	-96	-95	N/A
9/30/2018	N/A	-96	-79	-78	N/A
6/30/2018	N/A	-77	-60	-58	N/A
3/31/2018	N/A	-60	-49	-47	N/A
12/31/2017	N/A	-41	-41	-40	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: TCDA.Q is forecast to remain unprofitable over the next 3 years.

Beneficios vs. Mercado: TCDA.Q is forecast to remain unprofitable over the next 3 years.

Beneficios de alto crecimiento: TCDA.Q is forecast to remain unprofitable over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if TCDA.Q's revenue is forecast to grow faster than the US market.

Ingresos de alto crecimiento: TCDA.Q is forecast to have no revenue next year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if TCDA.Q's Return on Equity is forecast to be high in 3 years time

This company is no longer active

Tricida Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$8.00

Price target decreased to US$15.33

Price target increased to US$16.75

Price target decreased to US$15.50

Price target increased to US$17.50

Price target increased to US$17.50

Recent updates

Tricida, Inc. Announces Resignation of David Bonita as Director

Tricida, Inc.(OTCPK:TCDA.Q) dropped from NASDAQ Composite Index

Tricida Receives Delisting Notice from Nasdaq

Motion for Asset Sale Filed by Tricida, Inc.

Tricida, Inc. Filed for Bankruptcy

Tricida Receives Non-Compliance Notice from Nasdaq

Tricida Receives A Notice from Nasdaq Regarding Minimum Bid Price

Price target decreased to US$8.00

Insufficient new directors

Tricida, Inc Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Price target decreased to US$15.33

Tricida, Inc. announced that it expects to receive $125 million in funding

Tricida enters $125M debt facility

Tricida: Important Binary Event Coming Up

Tricida, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target increased to US$16.75

Price target decreased to US$15.50

Tricida, Inc Announces Administrative Stop of the VALOR-CKD Trial

Tricida, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$17.50

Insufficient new directors

Tricida, Inc., Annual General Meeting, Jun 15, 2022

Price target increased to US$17.50

Tricida, Inc. Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

Board Member notifies of intention to sell stock

Price target increased to US$20.00

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Board Member notifies of intention to sell stock

Tricida, Inc.(NasdaqGS:TCDA) dropped from Russell 2500 Growth Index

Board Member notifies of intention to sell stock

Tricida, Inc. Provides Update on FDA Interactions

Tricida, Inc. Appoints Geoffrey Parker as Chief Operating Officer

Robbins Geller Rudman & Dowd LLP Announces Lead Plaintiff Deadline in the Tricida, Inc. Class Action Lawsuit

New 90-day low: US$6.57

Board Member notifies of intention to sell stock

Block & Leviton LLP Sues Tricida, Inc. for Violations of the Federal Securities Laws

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Tricida, Inc

Law Offices of Howard G. Smith Announces the Filing of Securities Class Action on Behalf of Tricida, Inc. Investors

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Tricida, Inc

Board Member notifies of intention to sell stock

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

CFO & Executive VP recently bought US$102k worth of stock

Tricida, Inc. Announces Updates on Veverimer Development Program, Regulatory Status and New Patent Extending Protection Through 2038

Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%

Tricida, Inc. Announces Executive Changes

Tricida's Veverimer CRL And Regulatory Updates: An Analysis

Price target lowered to US$13.50

Price target raised to US$22.67

Tricida, Inc. Announces Susannah Cantrell Will Depart from the Position as Executive Vice President and Chief Commercial Officer, Effective from October 30, 2020

Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

New 90-day low: US$8.29

New 90-day low: US$9.33

Tricida, Inc.(NasdaqGS:TCDA) dropped from S&P Pharmaceuticals Select Industry Index

New 90-day low - US$13.24

Price target lowered to US$45.33

New 90-day low - US$15.64

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento